Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

Impact · against what's priced in

The news is a modest catalyst for Alphabet as it provides concrete progress toward generating option value from 'Other Bets,' which the market currently ignores. For J&J and Novartis, the partnership is largely reflected in current valuations, though the potential to hit long-term oncology targets remains a distant prospect.

GOOGL+0.20: Challenges what's priced in
The price assumes

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

What matters in this story

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

What matters in this story

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

How each ticker is affected

Track these names every morning.

Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk

Who Gets Paid for AI?

AI Spending Fears Hammer Big Tech Stocks

Anthropic's Gross Margin Rocketed to 85% From 12% in a Year, but the S-1 Warns It Won't Last

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

What matters in this story

Next reads from the same story arc

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

What matters in this story

Next reads from the same story arc

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

How each ticker is affected

Track these names every morning.

Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk

Who Gets Paid for AI?

AI Spending Fears Hammer Big Tech Stocks

Anthropic's Gross Margin Rocketed to 85% From 12% in a Year, but the S-1 Warns It Won't Last